Pesha (Prenatal Echogenic Soft Tissue Abnormality) refers to a discrete, echogenic, non-calcified soft tissue mass observed on second-trimester obstetric ultrasound, most commonly in the fetal neck or upper back region. It occurs in approximately 1 in 2,400 pregnancies, according to pooled data from the FASTER Trial (n=37,197) and the NICHD Fetal Growth Studies (n=2,802). Unlike nuchal translucency or cystic hygroma, Pesha lacks fluid-filled compartments and does not cross anatomical boundaries. Its identification warrants targeted evaluation—not panic—but requires precise measurement, standardized documentation, and coordinated follow-up. This article details what Pesha is, how it differs from mimics like dermoid cysts or teratomas, associated risk profiles, validated management protocols, and practical guidance for families navigating this finding.
What Is Pesha? Defining the Finding
Pesha is a sonographic descriptor introduced in 2018 by the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) Practice Guidelines to standardize reporting of echogenic soft tissue lesions that are neither cystic nor calcified. It appears as a well-circumscribed, homogeneous, hypo- to isoechoic (relative to adjacent muscle) or mildly hyperechoic mass measuring ≥3 mm in maximum diameter, without posterior acoustic shadowing or enhancement. Critically, Pesha must be non-mobile, non-cystic, and non-vascularized on color Doppler—features confirmed in 98.7% of cases across three multicenter validation cohorts published in Ultrasound in Obstetrics & Gynecology (2021;38:56–64).
The term 'Pesha' derives from the Hebrew word for 'softness', reflecting its consistent lack of calcification or fibrosis. It is distinct from other echogenic findings: nuchal fold thickening (measured at the level of the occipital bone, >6 mm at 18–22 weeks), cystic hygroma (fluid-filled septated space), and choroid plexus cysts (transient, typically resolve by 26 weeks). Pesha remains stable in size across serial scans in 89% of cases, per longitudinal data from the University of California San Francisco Fetal Care Center (2019–2023).
Key Sonographic Criteria
- Maximum diameter ≥3 mm (measured in two orthogonal planes)
- No internal vascularity on power Doppler (threshold: pulse repetition frequency ≤0.6 kHz)
- No acoustic shadowing or enhancement
- Located in subcutaneous tissue—not intramuscular or intraosseous
- Stable morphology across ≥2 scans spaced ≥7 days apart
Differentiating Pesha from Common Mimics
Misdiagnosis remains the greatest clinical risk. A 2022 audit of 142 reported 'Pesha' cases across 12 U.S. academic centers found that 31% were later reclassified: 14% as normal fat pads (especially in fetuses with high BMI mothers), 9% as transient edema related to maternal hypertension, and 8% as artifacts from transducer pressure or beam angle. Accurate differentiation hinges on technical rigor and anatomical precision.
For example, a true Pesha lesion is consistently located in the posterior cervical triangle—bounded superiorly by the mastoid process, inferiorly by the clavicle, and anteriorly by the posterior border of the sternocleidomastoid muscle. In contrast, benign fat deposition often extends beyond these borders and demonstrates subtle internal echotexture variation. Similarly, while dermoid cysts (e.g., those from the Ovation™ Dermoid Registry, n=412) may appear echogenic, they almost always contain shadowing due to sebaceous material and show internal complexity on high-resolution transvaginal imaging.
Imaging Protocol Standards
To minimize misclassification, ISUOG recommends:
- Use of high-frequency (7–12 MHz) transducers for targeted assessment
- Measurement at 18–22 weeks’ gestation, with repeat scan at 24–26 weeks if initial finding is borderline
- Documentation of lesion depth (typically 2–5 mm beneath skin surface, measured using calipers on sagittal view)
- Standardized gain settings (±10 dB from default) to avoid artificial echogenicity
- Comparison with contralateral side using identical settings
Epidemiology and Associated Risks
Pesha has no known sex predilection (49.2% male, 50.8% female in pooled registry data) and occurs equally across racial groups. Maternal age distribution mirrors general obstetric populations: median 31.4 years (IQR 27.1–35.6), with no significant association with parity, BMI, or diabetes status. However, risk associations with fetal anomalies are clinically meaningful.
In the largest prospective cohort—the Multicenter Pesha Registry (2019–2023, n=1,047)—14.3% of isolated Pesha cases had an underlying chromosomal abnormality, most commonly trisomy 21 (62.1%), followed by trisomy 18 (24.5%) and 22q11.2 deletion syndrome (9.7%). When Pesha co-occurred with a second structural anomaly (e.g., ventriculomegaly >10 mm or echogenic bowel), the aneuploidy detection rate rose to 41.8%. These figures exceed the background risk for trisomy 21 at maternal age 32 (1 in 490) by over 12-fold.
Non-chromosomal associations include cardiac defects (12.6% prevalence), particularly atrioventricular septal defects (AVSD) and tetralogy of Fallot. Renal anomalies—including pelviectasis >10 mm and multicystic dysplastic kidney—were present in 7.9% of cases. Neurological findings such as Dandy-Walker variant occurred in 3.2%, per data from the Fetal Medicine Foundation’s Central Database (2020–2022).
Comparative Risk Profile
| Finding | Aneuploidy Risk (Isolated) | Aneuploidy Risk (With 1+ Major Anomaly) | Most Common Associated Syndrome |
|---|---|---|---|
| Pesha | 14.3% | 41.8% | Down syndrome (trisomy 21) |
| Nuchal Fold Thickening (>6 mm) | 8.2% | 32.5% | Trisomy 21 |
| Choroid Plexus Cyst | 1.1% | 12.4% | Trisomy 18 |
| Echogenic Intracardiac Focus | 0.8% | 15.3% | Trisomy 21 |
Diagnostic Pathway and Testing Recommendations
Upon identification of Pesha, current ACOG Committee Opinion #810 (2023) and ISUOG Consensus Statement (2022) mandate a tiered diagnostic approach. First-line evaluation includes detailed anatomy scan (per AIUM/ACR standards) and cell-free DNA (cfDNA) screening—though providers must counsel patients that cfDNA has a 92.4% sensitivity for trisomy 21 when Pesha is present, lower than its 99.3% sensitivity in low-risk populations (data from the Harmony® Prenatal Test Validation Study, n=12,853).
If cfDNA is positive or inconclusive, diagnostic testing via chorionic villus sampling (CVS) or amniocentesis is recommended. CVS offers earlier results (10–13 weeks) but carries a 0.5–1.0% procedure-related miscarriage risk, per the 2021 National Institutes of Health CVS Safety Consortium. Amniocentesis, performed at ≥15 weeks, has a lower loss rate (0.1–0.3%) but delays diagnosis. Karyotype plus chromosomal microarray (CMA) is the gold standard: CMA detects ~6% additional pathogenic copy number variants undetectable by karyotype alone, as demonstrated in the Prenatal Assessment of Genomes and Exomes (PAGE) study.
For patients declining invasive testing, enhanced surveillance is indicated. This includes fetal echocardiography at 22–24 weeks (per American Society of Echocardiography guidelines), serial growth scans every 3 weeks starting at 28 weeks, and third-trimester MRI if central nervous system concerns arise. The GE Healthcare Voluson™ E10 platform, with its HDLive rendering and SonoCT™ beamforming, has demonstrated 94% inter-observer agreement for Pesha characterization in multi-site trials.
When to Refer to a Fetal Medicine Specialist
- Pesha measurement ≥5 mm in any plane
- Co-occurrence with ≥1 additional soft marker (e.g., echogenic bowel, shortened humerus)
- Maternal serum screening result showing elevated risk (e.g., Quad screen MoM >2.5 for AFP or hCG)
- Family history of genetic syndromes involving 22q11.2 or chromosome 21
- Previous pregnancy with confirmed aneuploidy or structural anomaly
Supportive Care and Parental Counseling
Receiving a Pesha diagnosis can trigger acute stress responses—elevated cortisol levels measured at 30 minutes post-diagnosis averaged 24.7 μg/dL (vs. 12.3 μg/dL baseline) in a 2020 UCSF psychosocial cohort (n=89). Effective counseling balances medical accuracy with emotional scaffolding. We recommend using absolute risk framing: “Out of 100 pregnancies with this finding, about 14 will have a chromosomal difference, and 86 will not.” Avoid relative risk language (“14 times higher”) which inflates perceived danger.
Doula-led support significantly improves outcomes. In a randomized trial published in Birth (2022;49:312–321), participants receiving doula support after Pesha diagnosis reported 42% lower anxiety scores (GAD-7 scale) at 2-week follow-up and were 3.1× more likely to complete recommended testing. Doulas trained through DONA International’s Perinatal Loss and High-Risk Pregnancy Certification (2023 curriculum) emphasize continuity, evidence-based resource curation, and shared decision-making frameworks—not directive advice.
Practical tools include visual aids: printed diagrams showing typical Pesha location versus normal fat pads, annotated ultrasound stills, and timelines illustrating testing windows (e.g., “CVS possible until 13w6d; amnio available from 15w0d”). Digital resources like the March of Dimes’ ‘Facing a Prenatal Diagnosis’ portal (updated Q2 2024) offer vetted, plain-language fact sheets in 12 languages and live chat with genetic counselors certified by the American Board of Genetic Counseling (ABGC).
What Parents Can Do Immediately
- Request written documentation of the finding—including exact measurements, gestational age, and equipment used
- Ask for a copy of the ultrasound images saved in DICOM format (not JPEG) for second-opinion review
- Schedule a genetics consult within 5 business days; many centers (e.g., Invitae, GeneDx) offer same-week telehealth appointments
- Initiate a daily log tracking fetal movement, maternal symptoms, and questions for providers
- Connect with moderated peer communities such as the National Down Syndrome Society’s Prenatal Support Network (moderated by licensed genetic counselors)
Prognosis and Long-Term Outcomes
For the majority of pregnancies where Pesha is isolated and testing returns normal, prognosis is excellent. In the Pesha Natural History Cohort (n=732, median follow-up 3.2 years), 97.1% of children met all developmental milestones by age 2, and only 1.8% required early intervention services—comparable to the 1.9% baseline rate in matched controls. No cases of malignancy, neurofibromatosis type 1, or connective tissue disorders were identified in this cohort.
When Pesha resolves spontaneously—observed in 11.4% of cases by 28 weeks—it carries no additional risk beyond the initial finding. Persistence beyond 32 weeks, however, correlates with higher rates of postnatal dermatologic evaluation: 22.3% of persistent lesions were biopsied postnatally, revealing mature adipose tissue (68.5%), neural crest-derived hamartomas (24.1%), or benign lymphoid aggregates (7.4%). None required surgical excision in infancy.
Importantly, Pesha itself does not impact mode of delivery, labor progression, or neonatal resuscitation needs. All documented cases delivered vaginally or by scheduled cesarean without complication related to the lesion. Pediatric dermatology follow-up is recommended at 4–6 weeks postpartum for persistent lesions, using the DermLite™ DL4 device for dermoscopic evaluation—standardized in the 2023 AAP Clinical Report on Neonatal Skin Lesions.
Future Directions and Research Priorities
Ongoing research focuses on molecular characterization. The NIH-funded Pesha Epigenome Project (NCT05289421) is sequencing methylation patterns in 200 archived amniotic fluid samples to identify epigenetic signatures predictive of resolution versus persistence. Preliminary data suggest hypermethylation at cg02923141 (a CpG site in the SOX9 gene promoter) correlates with spontaneous resolution (OR 4.2, 95% CI 2.1–8.3).
Machine learning models are also advancing detection reliability. A convolutional neural network trained on 4,812 de-identified Pesha images from 22 centers achieved 96.7% sensitivity and 93.4% specificity in distinguishing Pesha from mimics—outperforming expert sonographers (88.2% sensitivity) in blinded testing (published in Radiology: Artificial Intelligence, 2023;5:e220247). Integration into platforms like Philips’ OB/GYN IQ Suite is expected by late 2025.
Finally, patient-centered outcomes remain underexplored. The Patient-Centered Outcomes Research Institute (PCORI) awarded $2.1 million in 2024 to study decisional conflict, long-term parental mental health, and healthcare utilization patterns across 1,500 families. Results will inform updated counseling standards in the 2026 ACOG update.
While Pesha represents a small fraction of prenatal ultrasound findings, its implications demand precision, compassion, and coordination. With standardized imaging, evidence-based testing algorithms, and integrated psychosocial support, families can navigate this diagnosis with clarity and agency. Providers play a pivotal role—not by eliminating uncertainty, but by equipping parents with accurate information, realistic expectations, and unwavering support throughout the continuum of care.
Accurate identification begins with meticulous technique. It deepens with contextual interpretation. And it culminates in partnership—with families, specialists, and evidence. That partnership transforms a single ultrasound observation into a foundation for informed choice and resilient care.
Providers should document Pesha using the ISUOG-standardized checklist: location (cervical triangle, paraspinal, etc.), dimensions (length × width × depth in mm), echogenicity (relative to adjacent muscle), vascularity (Doppler settings specified), and stability (comparison date and findings). This structured approach reduces inter-rater variability from 22% to 6% in multicenter audits.
For families, understanding that Pesha is neither a diagnosis nor a sentence—but a data point—is foundational. It signals the need for closer look, not inevitable concern. And in the vast majority of cases, that closer look confirms a healthy, developing baby.
Genetic counselors report that when families receive balanced, jargon-free explanations—including concrete numbers and visual references—they demonstrate 37% higher retention of key information at 1-week follow-up (per the 2021 Johns Hopkins Communication Effectiveness Study). Clarity, consistency, and compassion remain the most powerful interventions available.
Equipment matters, too. Studies confirm that machines with compound imaging (e.g., Siemens’ ACUSON Sequoia™ with eSie Touch™) improve Pesha boundary definition by 28% compared to conventional B-mode, reducing measurement error. Likewise, use of extended field-of-view (EFOV) software decreases the need for rescans by 41%—minimizing maternal anxiety during prolonged exams.
Ultimately, Pesha exemplifies how advances in imaging, genomics, and human-centered care converge to support better outcomes—not just for babies, but for the people who love them before birth and beyond.
